% | $
Quotes you view appear here for quick access.

ImmunoGen, Inc. Message Board

  • bioimmunomabman bioimmunomabman Aug 16, 2013 9:18 AM Flag

    Fiercebiotech article on dealmaking

    Good article in FierceBiotech on deal making showing the focus for biotech is completing phase II proof of concept. If IMGN could ever successfully design and complete a phase II...I think they need more horsepower in clinical design. Maybe they rely on CRO's and consultants, but so far the results are unacceptable and require rapid improvement before they have another debacle.

    Speaking of debacles. they really know how to step into the shyte on the cc's...too much discussion about side effects, they failed to answer the questions with confidence and left the door open to the short attack. They need better prep to anticipate questions and better control over the analysts, no questions from UBS. Perhaps if they were more shareholder friendly, they might be able to anticipate the hard questions.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • very interesting article from fiercebiotech (In pharma, incremental innovation lives on). The phrase: "fail early, fail cheap" rang a bell with me for some reason.

      I hope IMGN follows such an approach instead of stringing along a failure until the very last moment. ie n901

      Sentiment: Buy

2.68+0.03(+1.13%)Sep 30 4:00 PMEDT